Previous 10 | Next 10 |
home / stock / gikly / gikly news
The following slide deck was published by Grifols, S.A. in conjunction with this event. For further details see: Grifols presents at 2021 investor and analyst day - slideshow
Grifols ([[GIKLY]]) announces that it has begun commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin for hepatitis B postexposure prophylaxis.The new formulation, which was approved by the U.S. FDA in December 2020, uses a unique caprylate chromatography process, w...
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B - The new formulation delivers anti-hepatitis B virus antibodies using a unique and sophisticated caprylate chromatography process - Grifols ...
Grifols operates in the very attractive and lucrative plasma business. The plasma-supply chain has been disrupted by the pandemic but the situation should normalize with the vaccination. Even though some new medicines could potentially disrupt the market, we believe related fears ...
Grifols installs first-ever DG Reader Net analyzer in North America - ThedaCare Medical Center-Wild Rose in Wisconsin is the first hospital in the U.S. and Canada to implement the DG Reader Net analyzer, helping automate pre-transfusion blood type matching and enhance patient sa...
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year -- Prestigious healthcare research firm reaffirms PharmacyKeeper Verification as the No. 1 product for Intravenous (IV) Workflow Management -- PharmacyKeeper Verification is a strategic part of ...
Grifols (GIKLY) announced the start of a clinical trial to evaluate the safety and efficacy of a new COVID-19 drug, containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.Based on the Grifols immunoglobulin Gamunex®-C, the treatment aims t...
Grifols partners with TRC Healthcare to streamline intravenous compounding education -- The integration of Grifols PharmacyKeeper and clinical education resources from TRC Healthcare will help pharmacy leaders by delivering the most current and relevant evidence-based education ...
Investment Thesis CSL Limited ( CSLLY ) has yet to fully recover from the plasma shortages experienced during the lockdowns. The impact on production is likely to materialize just as elective surgeries resume. The influenza vaccine sales can pick up the slack as fears mount over a flu outb...
This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...
News, Short Squeeze, Breakout and More Instantly...
Grifols SA Barcelona ADR Company Name:
GIKLY Stock Symbol:
OTCMKTS Market:
Grifols SA Barcelona ADR Website:
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...